Generic Oncology Sterile Injectable Market, by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Can

Generic Oncology Sterile Injectable Market, by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies,  Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectables products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of few cancer products by 86% in March 2017.
Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry of product is expected to fuel growth of the generic oncology sterile injectables market during the forecast period. The emergence of biosimilars have also impacted the growth of generics oncology sterile products. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars have a major share in Europe and in the U.S. since 2013 and 2015, respectively, and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.
Market Dynamics
Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the World Health Organization, in 2021, around 18.1 million new cases of cancer and 9.6 million deaths were reported, globally.
However, lack of awareness amongst the people in low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the generic oncology sterile injectables market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer’s (IARC) report of 2013, cervical cancer is mostly prevalent in low-income countries of sub-Saharan Africa.
Key features of the study:
This report provides in-depth analysis of the global generic oncology sterile injectable market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global generic oncology sterile injectable market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global generic oncology sterile injectable market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers of generic oncology sterile injectable market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Generic Oncology Sterile Injectable Market, by Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
Global Generic Oncology Sterile Injectable Market, by Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
Global Generic Oncology Sterile Injectable Market, by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Generic Oncology Sterile Injectable Market, by Region:
North America
By Country:
U.S.
Canada
By Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
By Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
By Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
By Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
By Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
By Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product Type:
Chemotherapy
Alkylating agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
Monoclonal Antibodies
Cytokines
Peptide Hormones
By Disease Indication:
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Eli Lilly & Company*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Biocon Ltd.
Baxter International Inc.
Hikma Pharmaceuticals PLC
Mylan N.V.
Sandoz International GmbH
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.